The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Karl Weiss

Department of Infectious Diseases and Microbiology

Maisonneuve-Rosemont Hospital

Faculty of Medicine

University of Montreal



Name/email consistency: high



  • Department of Infectious Diseases and Microbiology, Maisonneuve-Rosemont Hospital, Faculty of Medicine, University of Montreal, Canada. 2001 - 2012
  • Maisonneuve-Rosemont Hospital, Faculty of Medicine, University of Montreal, 5415 L'Assomption. 2007
  • Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec. 2000 - 2001


  1. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Weiss, K., Allgren, R.L., Sellers, S. Clin. Infect. Dis. (2012) [Pubmed]
  2. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Weiss, K. Int. J. Antimicrob. Agents (2009) [Pubmed]
  3. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Weiss, K., Boisvert, A., Chagnon, M., Duchesne, C., Habash, S., Lepage, Y., Letourneau, J., Raty, J., Savoie, M. Infect. Control. Hosp. Epidemiol (2009) [Pubmed]
  4. Clostridium difficile and fluoroquinolones: is there a link?. Weiss, K. Int. J. Antimicrob. Agents (2009) [Pubmed]
  5. Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Weiss, K., Bergeron, L., Bernatchez, H., Goyette, M., Savoie, M., Thirion, D. Int. J. Antimicrob. Agents (2007) [Pubmed]
  6. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Weiss, K., Tillotson, G.S. Chest (2005) [Pubmed]
  7. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Weiss, K., Low, D.E., Cortes, L., Beaupre, A., Gauthier, R., Gregoire, P., Legare, M., Nepveu, F., Thibert, D., Tremblay, C., Tremblay, J. Can. Respir. J. (2004) [Pubmed]
  8. An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Weiss, K., Vanjaka, A. Clin. Ther (2002) [Pubmed]
  9. Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. Weiss, K., De Azavedo, J., Restieri, C., Galarneau, L.A., Gourdeau, M., Harvey, P., Paradis, J.F., Salim, K., Low, D.E. J. Antimicrob. Chemother. (2001) [Pubmed]
  10. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Weiss, K., Restieri, C., Gauthier, R., Laverdière, M., McGeer, A., Davidson, R.J., Kilburn, L., Bast, D.J., de Azavedo, J., Low, D.E. Clin. Infect. Dis. (2001) [Pubmed]
  11. In vitro activity of a novel ketolide ABT-773 against invasive strains of Streptococcus pneumoniae. Weiss, K., de Azavedo, J., Restieri, C., Quach, C., Laverdiere, M., Rubin, E., Gourdeau, M., Low, D.E. J. Antimicrob. Chemother. (2001) [Pubmed]
  12. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. Weiss, K., Restieri, C., De Carolis, E., Laverdière, M., Guay, H. J. Antimicrob. Chemother. (2000) [Pubmed]
WikiGenes - Universities